Editas Medicine financials
$2.59+3.19%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.9M | $2.8M | $24.7M | $7.5M | $3.6M | $4.7M | $30.6M | $61.0K | $513.0K | $1.1M | $60.0M | $5.3M |
| Gross profit | $11.9M | $2.8M | $24.7M | $7.5M | $3.6M | $4.7M | $30.6M | $61.0K | $513.0K | $1.1M | $60.0M | $5.3M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$18.6M | -$25.0M | -$7.8M | -$24.5M | -$51.5M | -$76.2M | -$46.6M | -$65.7M | -$71.9M | -$67.0M | -$24.0M | -$50.2M |
| Net income | -$18.2M | -$25.0M | -$5.6M | -$25.1M | -$53.2M | -$76.1M | -$45.4M | -$62.1M | -$67.6M | -$62.0M | -$18.9M | -$45.0M |
| Net margin | −153.3% | −882.4% | −22.7% | −333.0% | −1487.8% | −1633.5% | −148.3% | −101870.5% | −13178.8% | −5458.1% | −31.4% | −843.7% |
| Diluted EPS | $-0.15 | $-0.26 | $-0.06 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.23 | $-0.55 |
| EBITDA | -$19.5M | -$24.5M | -$13.2M | -$23.8M | -$23.6M | -$33.4M | -$33.0M | -$64.1M | -$70.5M | -$65.6M | -$22.5M | -$48.6M |
| Operating cash flow | -$29.6M | -$23.1M | -$36.4M | -$30.8M | -$50.2M | -$47.8M | -$50.8M | -$52.6M | -$57.1M | -$49.9M | -$22.2M | -$35.5M |
| Free cash flow | -$29.7M | -$23.2M | -$36.4M | -$31.3M | -$50.2M | -$47.9M | -$51.3M | -$55.5M | -$60.6M | -$51.7M | -$23.5M | -$35.7M |
| Diluted shares | 119.3M | 97.9M | 97.4M | 90.1M | 84.4M | 83.1M | 82.6M | 82.5M | 82.3M | 81.9M | 81.9M | 81.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $181.8M | $123.6M | $146.6M | $165.6M | $138.5M | $138.7M |
| Short-term investments | $29.8M | $0.00 | $0.00 | $0.00 | $40.0M | $82.3M |
| Total debt | $55.7M | $54.7M | $58.6M | $59.1M | $56.7M | $54.6M |
| Total assets | $237.4M | $149.3M | $186.5M | $201.8M | $210.6M | $263.7M |
| Total liabilities | $132.1M | $144.9M | $159.2M | $188.3M | $191.4M | $201.2M |
| Shareholders' equity | $105.3M | $4.4M | $27.3M | $13.5M | $19.2M | $62.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology